Looking for the next apple? This is the orchard.
The report, which has been prepared in accordance with the Marine Transportation Framework established by the
Eagle’s ESG Sustainability Report can be accessed at www.eagleships.com/ESG.
About
CONTACT
Company Contact:
Chief Financial Officer
Tel. +1 203-276-8100
Email: investor@eagleships.com
Media:
Tel. +1 212-359-2228
Source: Eagle Bulk Shipping Inc.
Kratos DRSS is a leading provider of products and solutions in support of ballistic missile targets, hypersonic systems, sub-orbital research, sounding rockets, directed energy and laser program systems. Work under this contract will be performed at a secure Kratos facility in
The mission of this flight experiment vehicle will be to support the development of innovative and enabling technologies for urgent requirements by providing flight tests and demonstration opportunities in relevant environments. This rapid testing capability will allow lower Technology Readiness Level (TRL) components to be matured faster for insertion into future missile programs.
Kratos is partnered with the Naval Surface Warfare Center Port Hueneme Division, White Sands Detachment,
About
Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended
Press Contact:
858-812-7302 Direct
Investor Information:
877-934-4687
investor@kratosdefense.com
Source: Kratos Defense & Security Solutions, Inc.
Image Credit: IAEA Image Bank (Flickr)
Sure, Robinhood provides the ability to invest in fractional shares, and you can trade 7 different
cryptocurrency coins, but can you buy 50 tons of physical uranium?
In a press release dated this past Tuesday, Uranium Trading Corporation (UTC) announced they were the facilitator of the purchase of uranium for a large multifamily office. The initial purchase amount is for 100,000 pounds of U3O8. Not too long ago a physical investment in U308 would have seemed impossible. Today the doors are opening on once undreamt-of investment fronts – holding this increasingly popular commodity is just another one.
Background
The demand for uranium is expected to exceed its supply in the near future. UTC, founded in 2018, was formed to provide the means for investors to invest in business opportunities in the civil uranium market. The means to transact in the fuel involves UTC, a corporation that directly invests in natural uranium oxide in concentrates (“U3O8”) and uranium hexafluoride (“UF6”) and a company named 92 Trading, LLC which will provide management services to UTC. 92 Trading is engaged in pursuing commercial business and providing trading opportunities in the international uranium market. Its objective is to generate value for UTC investors and provide a pathway for it to invest in the storage of physical uranium with the goal of achieving capital appreciation resulting from any price increases due to expected future fundamental supply and demand imbalances.
As it relates to this transaction for the family office, David Berklite, CEO of Uranium Trading Corp said, “We are excited to have the opportunity to open up a market that has historically been isolated from the financial investment community,” he added “This purchase comes at a time when supply is being shut in globally and demand from reactor new builds continues its accelerated growth trajectory. As an asset class, uranium as a commodity represents what we believe to be a compelling opportunity with almost no correlation to any other asset class.”
No other details about this transaction have been given. Channelchek reached out to spokesman for UTC, for further information. We will pass anything pertinent along to our readers as they respond. Channelchek also discussed this with Noble Capital Markets Senior Energy Analyst Michael Heim, he commented, “…there is definitely a trend towards more speculative uranium trading.” Heim followed with, “…they now trade uranium futures, @UXX.1 on CNBC and UX=F on Yahoo, but they are very thinly traded.”
Take-Away
The move away from carbon-based fuels has caused a move toward uranium as a possible replacement for reliable energy for electric generation. Uranium has come back into vogue just as some large mines have closed or reduced output. Investors are looking to capitalize on what they now see as a recipe for higher uranium prices. Most trade in mining companies (see partial list below), it now appears direct investment is not impossible.
Managing Editor, Channelchek
Suggested Content:
|
|
The Increasing Popularity of Uranium Investments
|
Recipe for Higher Uranium Prices
|
|
|
One-on-One With encore Energy
|
One-on-One with Energy Fuels
|
Sources:
https://www.sec.gov/Archives/edgar/data/1750407/000149315218014189/ex10-1.htm
|
|
|
Capstone Green Energy President & CEO Darren Jamison and CFO Eric Henchken make a formal corporate presentation. Afterwards, they are joined by Noble Capital Markets Senior Research Analyst Michael Heim for a Q & A session featuring questions asked by the live audience throughout the event. Research, News, and Advanced Market Data on CGRNInformation on upcoming live virtual roadshows
About Capstone Green Energy Capstone Green Energy (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) is a leading provider of customized microgrid solutions and on-site energy technology systems focused on helping customers around the globe meet their environmental, energy savings, and resiliency goals. Capstone Green Energy focuses on four key business lines. Through its Energy as a Service (EaaS) business, it offers rental solutions utilizing its microturbine energy systems and battery storage systems, comprehensive Factory Protection Plan (FPP) service contracts that guarantee life-cycle costs, as well as aftermarket parts. Energy Conversion Products are driven by the Company’s industry-leading, highly efficient, low-emission, resilient microturbine energy systems offering scalable solutions in addition to a broad range of customer-tailored solutions, including hybrid energy systems and larger frame industrial turbines. The Energy Storage Products business line designs and installs microgrid storage systems creating customized solutions using a combination of battery technologies and monitoring software. Through Hydrogen Energy Solutions, Capstone Green Energy offers customers a variety of hydrogen products, including the Company’s microturbine energy systems. |
Thursday, July 01, 2021
CoreCivic is a diversified government solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through corrections and detention management, a growing network of residential reentry centers to help address America’s recidivism crisis, and government real estate solutions. We are a publicly traded real estate investment trust and the nation’s largest owner of partnership correctional, detention and residential reentry facilities. We also believe we are the largest private owner of real estate used by U.S. government agencies. The Company has been a flexible and dependable partner for government for more than 35 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good.
Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Asset Sale. CoreCivic completed the sale of the remaining three non-core real estate assets: the 541,000 sq. ft. Social Security Administration building, the 277,000 sq. ft. Capital Commerce Center, and the 217,000 sq. ft. NARA Property. The aggregate sales price was $326 million. The Company had purchased the three buildings in 2018 for an aggregate gross purchase price of $293.6 million.
Net Proceeds. CoreCivic used $194.4 million of the sales proceeds to fully repay non-recourse mortgage notes associated with the SSA and Capital Commerce Center. The amount includes $32.5 million of prepayment premiums. Combining the net proceeds of $130 million with the nearly $30 million of net proceeds from earlier non-core sales, the Company exceeded its $150 net proceeds goal. The net proceeds …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
The report, which has been prepared in accordance with the Marine Transportation Framework established by the
Eagle’s ESG Sustainability Report can be accessed at www.eagleships.com/ESG.
About
CONTACT
Company Contact:
Chief Financial Officer
Tel. +1 203-276-8100
Email: investor@eagleships.com
Media:
Tel. +1 212-359-2228
Source: Eagle Bulk Shipping Inc.
FLORHAM PARK, N.J., July 01, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, was added to the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective on June 28, according to the FTSE Russell website.
Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
“Inclusion in the Russell Microcap Index underscores the progress we are making towards potentially improving the effectiveness of cancer therapy and increasing shareholder value by progressing our three (3) Phase 2 clinical programs for our lead HPV-cancer immunotherapy PDS0101,” said Dr. Frank Bedu-Addo, President and CEO of PDS Biotech. “Inclusion in the Index significantly benefits our Company and shareholders by elevating our visibility within the global investment community. We look forward to continuing to progress the clinical development of PDS0101 while also moving additional oncology pipeline products into human testing within the next year.”
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.
For more information on the Russell Microcap® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Company’s proprietary Versamune® T-cell activating technology platform. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells capable of targeting and killing tumors. Our immuno-oncology product candidates are initially being studied in combination therapy to potentially enhance efficacy without compounding toxicity across a range of cancer types. The company’s lead investigational cancer immunotherapy product PDS0101 is currently in three (3) Phase 2 clinical studies in HPV-associated cancers. Interim data for the company’s most advanced Phase 2 trial was reported in an oral presentation at the recent American Society of Clinical Oncology (ASCO) on June 7, 2021. The interim results demonstrated strong efficacy in treating the cancer in patients with advanced, treatment-resistant HPV16-positive anal, cervical, head and neck, vaginal and vulvar cancers. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The company’s pipeline products address various cancers including breast, colon, lung, prostate and ovarian cancers. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
About FTSE Russell
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.
FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.
A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit www.ftserussell.com.
Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® based products; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® based products and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Media & Investor Relations Contact:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: rich@cg.capital
Kratos DRSS is a leading provider of products and solutions in support of ballistic missile targets, hypersonic systems, sub-orbital research, sounding rockets, directed energy and laser program systems. Work under this contract will be performed at a secure Kratos facility in
The mission of this flight experiment vehicle will be to support the development of innovative and enabling technologies for urgent requirements by providing flight tests and demonstration opportunities in relevant environments. This rapid testing capability will allow lower Technology Readiness Level (TRL) components to be matured faster for insertion into future missile programs.
Kratos is partnered with the Naval Surface Warfare Center Port Hueneme Division, White Sands Detachment,
About
Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended
Press Contact:
858-812-7302 Direct
Investor Information:
877-934-4687
investor@kratosdefense.com
Source: Kratos Defense & Security Solutions, Inc.
